FDA Grants Breakthrough Therapy Designation for GSK's Osteosarcoma Treatment

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK's GSK'227, a B7-H3-targeted antibody-drug conjugate (ADC), aimed at treating relapsed or refractory osteosarcoma in adult patients who have not responded to at least two prior lines of therapy. This designation is supported by encouraging early data from the ARTEMIS-002 study, a Phase II, open-label, randomized, multi-center trial that evaluates the efficacy and safety of GSK'227 in osteosarcoma and other bone and soft tissue sarcomas.

Osteosarcoma, primarily affecting children and young adults, is the most common primary bone cancer. However, treatment options are severely limited once the disease recurs, underscoring the urgent need for effective therapies. The FDA's decision marks a significant step forward in addressing this high unmet medical need.

This is the third regulatory designation for GSK'227, following the Priority Medicines (PRIME) designation from the European Medicines Agency and the FDA's Breakthrough Therapy Designation for the treatment of relapsed or refractory small-cell lung cancer. GSK acquired exclusive worldwide rights to develop and commercialize GSK'227 from Hansoh Pharma in December 2023, excluding mainland China, Hong Kong, Macau, and Taiwan.

If approved, GSK'227 could represent a groundbreaking therapy for osteosarcoma patients, offering hope where current treatment options are limited. The development of GSK'227 underscores GSK's commitment to addressing critical gaps in cancer treatment, particularly for rare and aggressive forms of the disease.